| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Antimicrobial Stewardship | 4 | 2019 | 931 | 0.68 | Why? |
| Communicable Diseases | 4 | 2019 | 2148 | 0.64 | Why? |
| Lamivudine | 4 | 2018 | 210 | 0.63 | Why? |
| Atazanavir Sulfate | 4 | 2018 | 213 | 0.59 | Why? |
| Anti-HIV Agents | 8 | 2020 | 2209 | 0.48 | Why? |
| HIV Infections | 16 | 2021 | 11620 | 0.41 | Why? |
| Chloroquine | 3 | 2021 | 3152 | 0.41 | Why? |
| Antiretroviral Therapy, Highly Active | 7 | 2018 | 952 | 0.40 | Why? |
| Sleep Wake Disorders | 1 | 2020 | 1463 | 0.38 | Why? |
| Health Facilities | 1 | 2017 | 1230 | 0.37 | Why? |
| Survivors | 1 | 2020 | 2619 | 0.36 | Why? |
| Shock, Septic | 1 | 2018 | 1313 | 0.35 | Why? |
| Discitis | 2 | 2018 | 23 | 0.35 | Why? |
| Antihypertensive Agents | 1 | 2020 | 1962 | 0.34 | Why? |
| Bacteremia | 4 | 2018 | 1372 | 0.32 | Why? |
| HIV-1 | 8 | 2018 | 3365 | 0.31 | Why? |
| Reverse Transcriptase Inhibitors | 4 | 2018 | 309 | 0.30 | Why? |
| Acinetobacter Infections | 1 | 2008 | 273 | 0.29 | Why? |
| Acinetobacter baumannii | 1 | 2008 | 378 | 0.28 | Why? |
| Ritonavir | 5 | 2020 | 4212 | 0.26 | Why? |
| Candidiasis | 2 | 2018 | 334 | 0.25 | Why? |
| Hydroxychloroquine | 4 | 2021 | 12447 | 0.25 | Why? |
| Education, Medical | 2 | 2019 | 2461 | 0.25 | Why? |
| Klebsiella Infections | 2 | 2017 | 466 | 0.23 | Why? |
| Sepsis | 2 | 2019 | 3517 | 0.23 | Why? |
| Drug Resistance, Multiple, Bacterial | 2 | 2017 | 1115 | 0.23 | Why? |
| beta-Lactamases | 2 | 2019 | 759 | 0.22 | Why? |
| Legislation, Hospital | 1 | 2020 | 24 | 0.22 | Why? |
| Anti-Bacterial Agents | 7 | 2019 | 10083 | 0.22 | Why? |
| Antimalarials | 2 | 2021 | 2505 | 0.20 | Why? |
| Leishmaniasis, Visceral | 1 | 2000 | 85 | 0.20 | Why? |
| Somatoform Disorders | 1 | 2020 | 153 | 0.18 | Why? |
| Peptidyl-Dipeptidase A | 1 | 2020 | 9659 | 0.18 | Why? |
| Metronidazole | 1 | 2018 | 59 | 0.18 | Why? |
| Bone Diseases, Infectious | 1 | 1997 | 20 | 0.18 | Why? |
| Glucans | 1 | 2017 | 13 | 0.18 | Why? |
| AIDS-Related Opportunistic Infections | 1 | 2000 | 260 | 0.18 | Why? |
| beta-Lactam Resistance | 1 | 2019 | 150 | 0.17 | Why? |
| Liability, Legal | 1 | 2020 | 198 | 0.17 | Why? |
| Antibodies, Fungal | 1 | 2017 | 49 | 0.17 | Why? |
| HIV Protease Inhibitors | 4 | 2018 | 434 | 0.17 | Why? |
| Capsid Proteins | 1 | 2020 | 365 | 0.16 | Why? |
| Depression | 2 | 2021 | 14116 | 0.16 | Why? |
| Drug Therapy | 1 | 2019 | 280 | 0.16 | Why? |
| SARS Virus | 1 | 2020 | 13021 | 0.16 | Why? |
| Fungal Proteins | 1 | 2017 | 133 | 0.16 | Why? |
| Fever of Unknown Origin | 1 | 2017 | 93 | 0.16 | Why? |
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2017 | 170 | 0.15 | Why? |
| Fabry Disease | 1 | 2017 | 106 | 0.15 | Why? |
| Staphylococcal Infections | 3 | 2017 | 1099 | 0.15 | Why? |
| Candida albicans | 1 | 2017 | 217 | 0.15 | Why? |
| Drugs, Generic | 1 | 2017 | 136 | 0.15 | Why? |
| Anxiety | 2 | 2021 | 17311 | 0.15 | Why? |
| Enterobacteriaceae | 1 | 2019 | 395 | 0.14 | Why? |
| Expert Testimony | 1 | 2019 | 658 | 0.14 | Why? |
| Drug Resistance, Bacterial | 3 | 2019 | 1414 | 0.14 | Why? |
| Schools, Medical | 2 | 2019 | 793 | 0.14 | Why? |
| Curriculum | 2 | 2019 | 3083 | 0.14 | Why? |
| Klebsiella pneumoniae | 2 | 2017 | 658 | 0.14 | Why? |
| Carbapenems | 1 | 2017 | 343 | 0.13 | Why? |
| Gram-Positive Bacterial Infections | 1 | 2018 | 323 | 0.13 | Why? |
| Azetidines | 1 | 2020 | 722 | 0.13 | Why? |
| Awareness | 1 | 2019 | 529 | 0.13 | Why? |
| Mutation | 5 | 2021 | 12376 | 0.13 | Why? |
| Immune System | 1 | 2003 | 1479 | 0.13 | Why? |
| Candidemia | 1 | 2018 | 353 | 0.13 | Why? |
| Arthritis | 1 | 1997 | 288 | 0.13 | Why? |
| Health Personnel | 2 | 2020 | 29646 | 0.13 | Why? |
| Obsessive-Compulsive Disorder | 1 | 2020 | 486 | 0.13 | Why? |
| HIV | 1 | 2020 | 1116 | 0.13 | Why? |
| Tenofovir | 1 | 2016 | 449 | 0.13 | Why? |
| Enterobacteriaceae Infections | 1 | 2019 | 529 | 0.12 | Why? |
| Sulfonamides | 2 | 2020 | 1294 | 0.12 | Why? |
| Gram-Negative Bacterial Infections | 1 | 2018 | 398 | 0.12 | Why? |
| Practice Guidelines as Topic | 1 | 2017 | 15421 | 0.12 | Why? |
| Humans | 55 | 2021 | 930598 | 0.12 | Why? |
| Italy | 9 | 2021 | 38444 | 0.11 | Why? |
| Immunomodulation | 1 | 2020 | 1472 | 0.11 | Why? |
| Heparin, Low-Molecular-Weight | 1 | 2021 | 1731 | 0.11 | Why? |
| Bacterial Proteins | 2 | 2018 | 1318 | 0.11 | Why? |
| Antiviral Agents | 3 | 2021 | 41703 | 0.11 | Why? |
| Clostridium Infections | 1 | 2018 | 595 | 0.11 | Why? |
| Methicillin-Resistant Staphylococcus aureus | 1 | 2017 | 711 | 0.10 | Why? |
| Genome, Viral | 3 | 2021 | 13157 | 0.10 | Why? |
| Leukocyte Count | 1 | 2020 | 3178 | 0.10 | Why? |
| Lipids | 1 | 2016 | 1079 | 0.10 | Why? |
| Anti-Infective Agents | 2 | 2019 | 1766 | 0.10 | Why? |
| Male | 30 | 2021 | 367725 | 0.10 | Why? |
| Immunodeficiency Virus, Feline | 1 | 2008 | 38 | 0.09 | Why? |
| Pyrones | 1 | 2008 | 29 | 0.09 | Why? |
| Blood Pressure | 1 | 2020 | 2198 | 0.09 | Why? |
| Suppuration | 2 | 2018 | 8 | 0.09 | Why? |
| Methicillin Resistance | 1 | 2008 | 77 | 0.09 | Why? |
| Students, Medical | 2 | 2019 | 4032 | 0.09 | Why? |
| Virus Diseases | 2 | 2019 | 3779 | 0.09 | Why? |
| Thrombophilia | 1 | 2021 | 1935 | 0.09 | Why? |
| Hospital Mortality | 3 | 2021 | 22087 | 0.09 | Why? |
| Lymphopenia | 1 | 2020 | 2669 | 0.09 | Why? |
| Liver Cirrhosis | 2 | 2019 | 1810 | 0.09 | Why? |
| Teaching | 1 | 2017 | 1208 | 0.09 | Why? |
| Female | 27 | 2021 | 380317 | 0.09 | Why? |
| Catheters, Indwelling | 1 | 2008 | 84 | 0.09 | Why? |
| Heparin | 1 | 2021 | 2600 | 0.09 | Why? |
| Middle Aged | 23 | 2021 | 270681 | 0.08 | Why? |
| Antifungal Agents | 1 | 2018 | 1828 | 0.08 | Why? |
| Hepatitis C | 1 | 2019 | 1514 | 0.08 | Why? |
| Cognitive Dysfunction | 1 | 2019 | 1389 | 0.08 | Why? |
| Internationality | 1 | 2020 | 3297 | 0.08 | Why? |
| Lymphocytes | 1 | 2020 | 3056 | 0.08 | Why? |
| Intensive Care Units | 4 | 2020 | 29594 | 0.08 | Why? |
| Drug Therapy, Combination | 5 | 2018 | 7268 | 0.08 | Why? |
| DNA, Viral | 1 | 2017 | 2521 | 0.08 | Why? |
| Treatment Outcome | 11 | 2021 | 51732 | 0.08 | Why? |
| Bacteria | 1 | 2017 | 1897 | 0.08 | Why? |
| beta-Lactams | 1 | 2008 | 210 | 0.08 | Why? |
| Cross Infection | 1 | 2008 | 8675 | 0.08 | Why? |
| Aged | 17 | 2021 | 215776 | 0.07 | Why? |
| Health Care Rationing | 1 | 2020 | 2558 | 0.07 | Why? |
| Europe | 2 | 2019 | 12702 | 0.07 | Why? |
| Virus Replication | 2 | 2020 | 14331 | 0.07 | Why? |
| Randomized Controlled Trials as Topic | 2 | 2021 | 10649 | 0.07 | Why? |
| Drug Combinations | 3 | 2020 | 3852 | 0.07 | Why? |
| Education, Medical, Undergraduate | 1 | 2017 | 1392 | 0.07 | Why? |
| Machine Learning | 1 | 2020 | 4395 | 0.07 | Why? |
| Cardiovascular Diseases | 2 | 2020 | 11497 | 0.06 | Why? |
| Neutrophils | 1 | 2020 | 5476 | 0.06 | Why? |
| Protein Binding | 1 | 2020 | 11430 | 0.06 | Why? |
| Biomarkers | 4 | 2019 | 23361 | 0.06 | Why? |
| Adult | 16 | 2021 | 244371 | 0.06 | Why? |
| Retrospective Studies | 13 | 2021 | 105322 | 0.06 | Why? |
| Pneumonia, Viral | 7 | 2020 | 243684 | 0.06 | Why? |
| Survival Analysis | 3 | 2021 | 7592 | 0.06 | Why? |
| Coronavirus Infections | 7 | 2020 | 253789 | 0.06 | Why? |
| Clinical Competence | 1 | 2017 | 3263 | 0.06 | Why? |
| Pyridines | 1 | 2008 | 680 | 0.06 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 5277 | 0.06 | Why? |
| Treatment Failure | 2 | 2018 | 2106 | 0.06 | Why? |
| Coinfection | 2 | 2019 | 6820 | 0.06 | Why? |
| Drug Resistance, Viral | 1 | 2008 | 1083 | 0.06 | Why? |
| Anti-Inflammatory Agents | 1 | 2020 | 6153 | 0.06 | Why? |
| Spike Glycoprotein, Coronavirus | 3 | 2021 | 37182 | 0.06 | Why? |
| Developing Countries | 1 | 2017 | 4283 | 0.05 | Why? |
| Triage | 1 | 2020 | 7151 | 0.05 | Why? |
| Pulmonary Embolism | 1 | 2020 | 4775 | 0.05 | Why? |
| Bacterial Infections | 3 | 2019 | 2229 | 0.05 | Why? |
| Mice | 1 | 2020 | 21357 | 0.05 | Why? |
| Pneumonia | 1 | 2020 | 5652 | 0.05 | Why? |
| Algorithms | 1 | 2017 | 7346 | 0.05 | Why? |
| Young Adult | 6 | 2020 | 93724 | 0.05 | Why? |
| Static Electricity | 1 | 2021 | 397 | 0.05 | Why? |
| Anticoagulants | 1 | 2021 | 9563 | 0.05 | Why? |
| Protein Conformation, beta-Strand | 1 | 2020 | 414 | 0.05 | Why? |
| Life Change Events | 1 | 2021 | 208 | 0.05 | Why? |
| Respiratory Insufficiency | 1 | 2020 | 7301 | 0.05 | Why? |
| Models, Molecular | 3 | 2020 | 7616 | 0.05 | Why? |
| Sacroiliac Joint | 1 | 1997 | 26 | 0.05 | Why? |
| Pandemics | 12 | 2021 | 389249 | 0.05 | Why? |
| Protein Conformation, alpha-Helical | 1 | 2020 | 530 | 0.05 | Why? |
| Recurrence | 2 | 2018 | 3675 | 0.04 | Why? |
| Public Health | 2 | 2021 | 16359 | 0.04 | Why? |
| Betacoronavirus | 6 | 2020 | 204454 | 0.04 | Why? |
| Therapeutic Equivalency | 1 | 2017 | 64 | 0.04 | Why? |
| Gentamicins | 1 | 2017 | 76 | 0.04 | Why? |
| Likelihood Functions | 1 | 2020 | 719 | 0.04 | Why? |
| Tablets | 1 | 2018 | 219 | 0.04 | Why? |
| Acquired Immunodeficiency Syndrome | 1 | 2003 | 533 | 0.04 | Why? |
| Pneumonia, Staphylococcal | 1 | 1996 | 38 | 0.04 | Why? |
| Dideoxynucleosides | 1 | 2016 | 92 | 0.04 | Why? |
| Viral Load | 4 | 2018 | 15850 | 0.04 | Why? |
| Minocycline | 1 | 2017 | 101 | 0.04 | Why? |
| Bacterial Toxins | 1 | 2018 | 185 | 0.04 | Why? |
| Protein Structure, Tertiary | 1 | 2021 | 1565 | 0.04 | Why? |
| Repressor Proteins | 1 | 2018 | 232 | 0.04 | Why? |
| Aged, 80 and over | 7 | 2021 | 88759 | 0.04 | Why? |
| Evolution, Molecular | 2 | 2020 | 3691 | 0.04 | Why? |
| Arthritis, Infectious | 1 | 1997 | 111 | 0.04 | Why? |
| Prospective Studies | 4 | 2019 | 43301 | 0.04 | Why? |
| Probability | 1 | 2020 | 923 | 0.04 | Why? |
| Osteomyelitis | 1 | 1997 | 131 | 0.04 | Why? |
| Off-Label Use | 1 | 2020 | 553 | 0.04 | Why? |
| Inflammation | 1 | 2018 | 13255 | 0.04 | Why? |
| Risk Factors | 6 | 2020 | 71621 | 0.04 | Why? |
| Oxazines | 1 | 2017 | 279 | 0.04 | Why? |
| Colistin | 1 | 2017 | 217 | 0.04 | Why? |
| Carbapenem-Resistant Enterobacteriaceae | 1 | 2017 | 214 | 0.04 | Why? |
| Geography | 1 | 2021 | 1801 | 0.04 | Why? |
| Cost Savings | 1 | 2017 | 296 | 0.04 | Why? |
| Educational Status | 1 | 2021 | 1451 | 0.03 | Why? |
| Purines | 1 | 2020 | 816 | 0.03 | Why? |
| Molecular Epidemiology | 1 | 2020 | 1638 | 0.03 | Why? |
| Unemployment | 1 | 2021 | 702 | 0.03 | Why? |
| Lymphadenopathy | 1 | 2020 | 444 | 0.03 | Why? |
| Gene Expression Regulation, Viral | 1 | 2020 | 925 | 0.03 | Why? |
| Glomerular Filtration Rate | 1 | 2020 | 1262 | 0.03 | Why? |
| Cohort Studies | 4 | 2019 | 36005 | 0.03 | Why? |
| Heterocyclic Compounds, 3-Ring | 1 | 2017 | 275 | 0.03 | Why? |
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2017 | 449 | 0.03 | Why? |
| Piperazines | 1 | 2017 | 445 | 0.03 | Why? |
| Drug Substitution | 1 | 2017 | 385 | 0.03 | Why? |
| Candida | 1 | 2018 | 425 | 0.03 | Why? |
| Drug Costs | 1 | 2017 | 313 | 0.03 | Why? |
| Microbial Viability | 1 | 2017 | 406 | 0.03 | Why? |
| Global Health | 1 | 2017 | 13911 | 0.03 | Why? |
| Rare Diseases | 1 | 2017 | 373 | 0.03 | Why? |
| Health Services Accessibility | 1 | 2017 | 10697 | 0.03 | Why? |
| Amino Acid Substitution | 1 | 2020 | 1706 | 0.03 | Why? |
| Open Reading Frames | 1 | 2020 | 1898 | 0.03 | Why? |
| Cluster Analysis | 1 | 2021 | 3001 | 0.03 | Why? |
| Autophagy | 1 | 2020 | 960 | 0.03 | Why? |
| CD4 Lymphocyte Count | 1 | 2017 | 1517 | 0.03 | Why? |
| Animals | 2 | 2020 | 78931 | 0.03 | Why? |
| Phylogeny | 2 | 2021 | 13341 | 0.03 | Why? |
| Communicable Disease Control | 1 | 2021 | 29620 | 0.03 | Why? |
| Lung | 1 | 2020 | 31049 | 0.03 | Why? |
| Pyridones | 1 | 2017 | 738 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2018 | 2324 | 0.03 | Why? |
| Case-Control Studies | 2 | 2008 | 17671 | 0.03 | Why? |
| Disease Models, Animal | 1 | 2008 | 10998 | 0.03 | Why? |
| RNA, Viral | 4 | 2018 | 32276 | 0.02 | Why? |
| Length of Stay | 2 | 2018 | 11042 | 0.02 | Why? |
| Phosphoproteins | 1 | 2020 | 4346 | 0.02 | Why? |
| Pyrazoles | 1 | 2020 | 1791 | 0.02 | Why? |
| Postoperative Complications | 1 | 2008 | 5861 | 0.02 | Why? |
| Health Surveys | 1 | 2021 | 2841 | 0.02 | Why? |
| Age Factors | 2 | 2021 | 21039 | 0.02 | Why? |
| Protein Conformation | 1 | 2020 | 4386 | 0.02 | Why? |
| Hospitalization | 1 | 2020 | 54280 | 0.02 | Why? |
| Radiography | 1 | 2017 | 1576 | 0.02 | Why? |
| Propensity Score | 1 | 2017 | 2690 | 0.02 | Why? |
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 9335 | 0.02 | Why? |
| Delayed Diagnosis | 1 | 2018 | 1529 | 0.02 | Why? |
| HIV Protease | 1 | 2008 | 86 | 0.02 | Why? |
| Blood Coagulation | 1 | 2021 | 2768 | 0.02 | Why? |
| Medication Adherence | 1 | 2017 | 1270 | 0.02 | Why? |
| Acute Disease | 1 | 2020 | 6029 | 0.02 | Why? |
| Cost-Benefit Analysis | 1 | 2017 | 2259 | 0.02 | Why? |
| Thrombocytopenia | 1 | 2020 | 2093 | 0.02 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 1261 | 0.02 | Why? |
| ROC Curve | 1 | 2018 | 6024 | 0.02 | Why? |
| Lopinavir | 1 | 2020 | 4308 | 0.02 | Why? |
| Prognosis | 2 | 2020 | 32490 | 0.02 | Why? |
| Adolescent | 4 | 2020 | 86841 | 0.02 | Why? |
| Azithromycin | 1 | 2020 | 3943 | 0.02 | Why? |
| Transients and Migrants | 1 | 2017 | 1468 | 0.02 | Why? |
| Community-Acquired Infections | 1 | 1996 | 2328 | 0.02 | Why? |
| C-Reactive Protein | 1 | 2020 | 7972 | 0.02 | Why? |
| Sex Factors | 1 | 2021 | 11014 | 0.02 | Why? |
| Fever | 1 | 2020 | 7795 | 0.02 | Why? |
| Communicable Diseases, Emerging | 1 | 2017 | 2523 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2017 | 7220 | 0.02 | Why? |
| Severity of Illness Index | 2 | 2021 | 48226 | 0.01 | Why? |
| Molecular Sequence Data | 1 | 2008 | 3198 | 0.01 | Why? |
| Cross-Sectional Studies | 2 | 2021 | 53120 | 0.01 | Why? |
| Drug Repositioning | 1 | 2020 | 5683 | 0.01 | Why? |
| Cats | 1 | 2008 | 1890 | 0.01 | Why? |
| Travel | 1 | 2020 | 7220 | 0.01 | Why? |
| Disease Progression | 1 | 2020 | 13580 | 0.01 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2003 | 12361 | 0.01 | Why? |
| Tertiary Care Centers | 1 | 2017 | 8248 | 0.01 | Why? |
| Incidence | 1 | 2000 | 25622 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2017 | 17020 | 0.01 | Why? |
| Health Knowledge, Attitudes, Practice | 1 | 2021 | 8811 | 0.01 | Why? |
| Selenomethionine | 1 | 1976 | 9 | 0.01 | Why? |
| Amino Acid Sequence | 1 | 2008 | 6049 | 0.01 | Why? |
| Time Factors | 1 | 2017 | 31397 | 0.01 | Why? |
| China | 1 | 2020 | 50654 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2017 | 21571 | 0.01 | Why? |
| Cell Line | 1 | 2008 | 12040 | 0.01 | Why? |
| Comorbidity | 1 | 2017 | 34796 | 0.01 | Why? |
| Pneumonia, Pneumocystis | 1 | 1996 | 322 | 0.01 | Why? |
| Substance Abuse, Intravenous | 1 | 1996 | 411 | 0.01 | Why? |
| Selenium | 1 | 1976 | 412 | 0.01 | Why? |
| Regression Analysis | 1 | 1996 | 2484 | 0.01 | Why? |
| Liver Neoplasms | 1 | 1976 | 1666 | 0.00 | Why? |
| Liver Diseases | 1 | 1976 | 2698 | 0.00 | Why? |
| Gold Colloid, Radioactive | 1 | 1976 | 1 | 0.00 | Why? |
| Radionuclide Imaging | 1 | 1976 | 184 | 0.00 | Why? |